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1216however, revealed multiple plaque rupture sites with thrombus for-
mation distal to the site of plaque rupture (Fig. 1E).
On the other hand, cerebral infarction may also be associated with
intact ﬁbrous caps wherein only plaque ﬁssure or erosion may
constitute the substrate for thrombus formation (Figs. 1F and 1G).
An 83-year-old man presented with sudden hemiplegia while he
had his breakfast. On the day after the onset, angiography revealed an
ipsilateral ischemic lesion with 80% stenosis of the right internal
carotid artery. We performed OCT to characterize the tissue com-
ponents of the culprit lesion. OCT revealed a plaque ﬁssure with
thrombus formation distal to the site of plaque ﬁssure (Fig. 1F).
Thrombus may also occur with an intact cap, which has been
described in coronary arteries as plaque erosion (1). A 72-year-old
man presented with stuttering hemiplegia. Fifteen days after onset,
angiography revealed an ipsilateral ischemic lesion with 80% stenosis
of the right internal carotid artery. The OCT revealed an intact
ﬁbrous cap with a double-lumen structure distal to the site of plaque
erosion (Fig. 1G). Although only a few examples of ICA imaging
are available in the literature, we expect that larger experience would
help better the understanding of carotid plaques and allow more
effective interventions in cerebral infarction.
Masanori Kawasaki, MD, PhD,* Shinichi Yoshimura, MD, PhD,
Kiyofumi Yamada, MD, Arihiro Hattori, MD,
Yoshiyuki Ishihara, MD, Kazuhiko Nishigaki, MD, PhD,
Genzou Takemura, MD, PhD, Toru Iwama, MD, PhD,
Shinya Minatoguchi, MD, PhD
*Department of Cardiology, Gifu University Graduate School of
Medicine, 1-1 Yanagido, Gifu 501-1194, Japan. E-mail: masanori@
ya2.so-net.ne.jp
http://dx.doi.org/10.1016/j.jcmg.2013.09.001
R E F E R E N C E S
1. Prati F, Uemura S, Souteyrand G, et al. OCT-based diagnosis and
management of STEMI associated with intact ﬁbrous cap. J Am Coll
Cardiol Img 2013;6:283–7.
2. Ozaki Y, Okumura M, Ismail TF, et al. Coronary CT angiographic
characteristics of culprit lesions in acute coronary syndromes not related to
plaque rupture as deﬁned by optical coherence tomography and angio-
scopy. Eur Heart J 2011;32:2814–23.
3. Yoshimura S, Kawasaki M, Hattori A, et al. Demonstration of intra-
luminal thrombus in the carotid artery by optical coherence tomography:
technical case report. Neurosurgery 2010;67(3 Suppl Operative):onsE305,
discussion onsE305.
4. Yadav JS, Wholey MH, Kuntz RE, et al., Stenting and Angioplasty With
Protection in Patients at High Risk for Endarterectomy Investigators.
Protected carotid-artery stenting versus endarterectomy in high-risk pa-
tients. N Engl J Med 2004;351:1493–501.
5. Schnaudigel S, Gröschel K, Pilgram SM, Kastrup A. New brain lesions
after carotid stenting versus carotid endarterectomy: a systematic review of
the literature. Stroke 2008;39:1911–9.
Myocardial Mechanics in
Noncontiguous HCM
Marked phenotypic heterogeneity is typical of hypertrophic car-
diomyopathy (HCM) with mostly localized and contiguous left
ventricular hypertrophy. Rarely, noncontiguous but focal left ven-
tricular hypertrophy is seen (1). A more comprehensive assessmentof HCM, including segmental distribution of hypertrophy resulting
in diverse patterns of HCM, has been described using cardiac
magnetic resonance (CMR), and centerline chord method on CMR
has been used to identify hypertrophied left ventricular segments
that may otherwise go unidentiﬁed on conventional 2-dimensional
echocardiography (2). A recent 3-dimensional CMR analysis
showed that the majority of patients with asymmetrical septal HCM
had a spiral pattern of hypertrophy, with extension toward complete
concentric apical involvement seen in 10% of these patients (3,4).
This ﬁnding suggests that asymmetric septal and apical HCM are
not completely separate phenotypes. The continuum of disease
involvement from base to apex can be underestimated in cross-
sectional imaging, especially on a conventional 2-dimensional
echocardiogram. However, the role of speckle tracking echocardi-
ography in identiﬁcation of such a continuum and in understanding
the mechanics of myocardial dysfunction, especially in patients with
noncontiguous HCM, is unclear.
We describe 5 cases of the noncontiguous left ventricular hy-
pertrophy phenotype of HCM. All of these patients had localized
hypertrophy involving the basal subaortic septal segment as well as
circumferential hypertrophy of noncontiguous apical segments, with
normal thickness (apparent sparing) of the intervening mid-
ventricular segments on conventional 2-dimensional echocardiog-
raphy and CMR. However, speckle tracking–derived myocardial
mechanics conﬁrmed reduced longitudinal systolic strain not only of
the hypertrophied segments of the apex and basal septum but also
revealed abnormally reduced strain of the nonhypertrophied inter-
vening midventricular segments (Fig. 1A). For comparison, we also
describe patients with isolated basal septal hypertrophy, basal and
midseptal hypertrophy, and apical hypertrophy. The myocardial
mechanics of these patients showed a reduced strain in the areas of
hypertrophy without involvement of the adjacent nonhypertrophied
segments (Fig. 1B).
Age of the patients in the 5 cases ranged from 35 to 73 years; 4
patients were male. Dyspnea was the common symptom. Three
patients had sleep apnea. Electrocardiograms of all patients revealed
marked T-wave inversions in precordial leads, typical of apical
HCM. Basal septal thickness ranged from 20 to 24 mm and apical
thickness from 15 to 20 mm. The midventricular thickness in all of
these patients was measured to be <12 mm in women and <13 mm
in men. There were varying degrees of systolic anterior motion of
mitral leaﬂets. Three patients had delayed gadolinium enhancement
(DGE) on CMR involving the apex and basal septum. All patients
received optimal medical treatment for symptoms attributable to left
ventricular outﬂow tract obstruction. Three patients underwent
alcohol septal ablation. Two patients received implantable
cardioverter-deﬁbrillators (ICDs) due to syncopal episodes and
DGE; a third patient had sudden cardiac death prior to ICD im-
plantation. Four patients underwent genetic testing, and no muta-
tions were found.
The age of the 5 patients with HCM used for comparison ranged
from 20 to 78 years; 2 were male. Three had basal septal hyper-
trophy, 1 had basal septal hypertrophy with some involvement of
the midventricle, and 1 had localized apical hypertrophy. Ventricular
wall thickness ranged from 19 to 22 mm, and mild left ventricular
outﬂow tract obstruction was present in septal variants. Also
included was a patient with genotype positive for a myosin heavy
chain 7 gene mutation but phenotype negative, with normal global
and regional longitudinal strain. One patient had a tropomyosin
Figure 1. Multimodality Evaluation of Noncontiguous Hypertrophic Cardiomyopathy and Evaluation of Hypertrophic Cardiomyopathy Used for Comparison
(A, top left) Illustrative electrocardiogram demonstrates left ventricular hypertrophy and giant T-wave inversions in leads V3 to V6, typical of apical hypertrophic
cardiomyopathy. (A, top right) Echocardiographic end-diastolic view (left) demonstrates marked apical and basal septal hypertrophy (arrows). The intervening
midventricular segments were spared of hypertrophy (arrowhead). End-systolic view (right) demonstrates systolic anterior motion of the mitral leaﬂet (asterisk).
(A, bottom left) End-diastolic magnetic resonance images show marked circumferential hypertrophy of apex and basal anterior septum with normal midventricular
segments. (A, bottom right) Illustrative speckle tracking echocardiographic polar plots demonstrate decreased global longitudinal systolic strain of 11%. Longi-
tudinal strain was normal at anterolateral and inferolateral segments, but decreased regional strain was noted not only in the anterobasal septum and apex but also
involved the intervening midventricular segments of normal thickness. This reﬂects that the myopathic process extended in a spiral manner from the basal septum
toward the apex. Illustrative echocardiographic images of patients with hypertrophic cardiomyopathy (HCM) used for comparison with noncontiguous HCM cases.
(B, left) Genotype-positive, phenotype-negative patient with normal global and regional longitudinal strain. (B, middle) Genotype-positive, phenotype-positive
patient with HCM localized to basal septum with decreased regional longitudinal strain localized to the corresponding areas of basal septum. (B, right)
Genotype-negative, phenotype-positive patient with HCM localized to the apex with decreased regional longitudinal strain localized to the corresponding areas of
apex. Nonhypertrophied segments demonstrate normal longitudinal strain. ANT ¼ anterior; ANT_SEPT ¼ anteroseptal; INF ¼ inferior; LAT ¼ lateral; POST ¼ posterior;
SEPT ¼ septal.
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1217gene mutation, and another had a mutation involving the cardiac
myosin-binding protein C gene. All patients received optimal
medical treatment based on symptoms. One received ICD for
nonsustained ventricular tachycardia and syncope.Similar to the recently described spiral pattern of hypertrophy
from the basal septum to the apex on CMR (3,4), our observations
suggest that myocardial mechanics can also identify this contin-
uum. In patients with noncontiguous HCM, speckle tracking
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1218echocardiography may unveil myocardial dysfunction in the
otherwise nonhypertrophied segments seen on conventional 2-
dimensional echocardiography and CMR imaging. The major
limitation of this study is the small number of patients; thus, these
ﬁndings need to be further validated. Although we continue to try
to solve the Rubik’s Cube that is the left ventricle in normal and
diseased states (5), especially with regard to HCM, further insights
provided by myocardial mechanics in these patients could help
guide our moves.
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De-Novo Thrombus Formation
and Latent Ligation Failure
Following LAA Exclusion
Left atrial appendage (LAA) exclusion is becoming a popular
alternative for patients with atrial ﬁbrillation who are ineligible for
long-term anticoagulation. The LAA exclusion system (Lariat Su-
ture Delivery Device, SentreHEART Inc., Redwood City, Cali-
fornia) was evaluated in a non-randomized single-center study with
an immediate closure success rate (<1 mm of residual ﬂow) of 95%,
which was maintained up to 90 days as assessed by transesophageal
echocardiography (TEE). The recent data has demonstrated safety
and efﬁcacy up to 1 year following the procedure with the success
rate of up to 98% with no reported late device-associated thrombi
(1,2). We report 3 cases of importance with respect to management
of antiplatelet and anticoagulation therapy.
Patient #1. The ﬁrst patient is a 63-year-old man with paroxysmal
atrial ﬁbrillation and prior splenic infarct who was ineligible for
long-term anticoagulation because of underlying coagulopathy sec-
ondary to cryptogenic cirrhosis with a history of esophageal variceal
bleed. Intraoperative TEE conﬁrmed closure of the LAA with noevidence of residual leak immediately following the Lariat procedure
(Fig. 1A). The patient received no post-operative antiplatelet or
anticoagulant therapy. Routine follow-up TEE 3 months later
showed that the LAA remained obliterated; however, there was a
new mobile thrombus in the LAA remnant attached to the atrial
wall (Fig. 1B). Despite his bleeding risk, the patient was started
on warfarin and remained asymptomatic with no neurologic
sequelae. Repeat TEE 2 months later showed complete resolution
of thrombus.
Patient #2. The second patient is a 75-year-old woman with
persistent atrial ﬁbrillation and history of ischemic stroke who
had extreme difﬁculty in maintaining a therapeutic international
normalized ratio on warfarin. During the LAA exclusion proce-
dure, it was difﬁcult to obtain complete ostial closure of the LAA.
Intraoperative imaging with angiography and TEE showed a
small pouch remnant, but suggested most of the distal trabecu-
lated appendage was closed (Fig. 1C). This patient also received
no post-operative antiplatelet or anticoagulant therapy. Routine
follow-up by TEE 3 months later revealed a thrombus in the
LAA, which no longer appeared to be closed, suggesting latent
ligation failure (Fig. 1D).
Patient #3. Finally, a 76-year-old man also with persistent
atrial ﬁbrillation was referred for the LAA exclusion procedure
because of a history of intracerebral hemorrhage in addition to
gastrointestinal bleed while on warfarin. Intraoperative TEE and
angiography conﬁrmed complete closure of the LAA with no re-
sidual leak (Fig. 1E). At discharge, the patient was maintained on
aspirin and clopidogrel only. Follow-up TEE 3 months later
demonstrated thrombus formation in the LAA, which was no
longer ligated (Fig. 1F). Because of the presence of thrombus,
aspirin and clopidogrel were discontinued, and the patient was
started on warfarin.
Initially, the role of post-procedure antithrombotic therapy was
largely unknown, although it was suggested the Lariat device
would allow freedom from warfarin, especially immediately
following the procedure. This is a contradistinction to another
LAA closure device (Watchman, Boston Scientiﬁc, Natick,
Massachusetts), which requires warfarin post-operatively for at
least 45 days while the device endothelializes (3). Initially, the role
of anticoagulation immediately following the Lariat procedure was
unclear and a nonsystematic approach was applied. Recent data
showing long-term results for thromboembolic event reduction are
confounded by the high proportion of patients (61%) on warfarin
at the time of last follow-up (approximately 1 year). Because this
data can not conﬁrm freedom from thrombus formation without
anticoagulation, recent recommendations by Bartus et al. (2) now
suggest that patients with a CHADS2 (congestive heart failure;
hypertension >140/90 mm Hg, or on hypertension medication;
age $75 years; diabetes mellitus; and prior stroke, transient
ischemic attack, or thromboembolism) score of 2 or higher
who can tolerate anticoagulation continue warfarin.
As noted in this report, we present a case series of 3 patients
who at 3-month follow-up TEE, had evidence of de novo
thrombus formation: 1 adjacent to the ligated LAA; and 2 within
the LAA that no longer appeared to be ligated. One patient
received antiplatelet therapy; however, none were initiated on
anticoagulant therapy immediately after the procedure. Based on
